Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.

Alessandro ParisiAlessio CortelliniMichela RobertoOlga VendittiDaniele SantiniEmanuela Dell'AquilaMarco StellatoPaolo MarchettiMario Alberto OcchipintiFederica ZorattoFederica MazzucaNicola TinariMichele De TursiLaura IezziClara NatoliMargherita RattiClaudio PizzoMichele GhidiniGiampiero PorzioCorrado FicorellaKatia Cannita

Published in: Journal of cancer research and clinical oncology (2019)

Efficacy of ramucirumab is confirmed in this "real-life" analysis. BWL seems not to have correlations with clinical outcomes in these patients, while BMI and ECOG-PS remain major prognostic factors. A possible explanation for the lack of prognostic effect of BWL might be the proportion of patients subjected to PTR in this series (52.5%).

Keyphrases

prognostic factors
body mass index
end stage renal disease
weight loss
ejection fraction
newly diagnosed
chronic kidney disease
bariatric surgery
physical activity
squamous cell carcinoma
lymph node
radiation therapy
roux en y gastric bypass
gastric bypass
obese patients